Zoetis Inc. (NYSE:ZTS) Shares Bought by Calamos Wealth Management LLC

Calamos Wealth Management LLC grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 21.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,030 shares of the company's stock after acquiring an additional 14,568 shares during the quarter. Calamos Wealth Management LLC's holdings in Zoetis were worth $13,691,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Calamos Advisors LLC increased its stake in Zoetis by 15.0% in the fourth quarter. Calamos Advisors LLC now owns 210,885 shares of the company's stock valued at $34,359,000 after purchasing an additional 27,579 shares during the last quarter. Childress Capital Advisors LLC increased its stake in Zoetis by 30.6% in the fourth quarter. Childress Capital Advisors LLC now owns 1,599 shares of the company's stock valued at $261,000 after purchasing an additional 375 shares during the last quarter. Alliance Wealth Advisors LLC UT increased its stake in Zoetis by 23.1% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 19,720 shares of the company's stock valued at $3,213,000 after purchasing an additional 3,700 shares during the last quarter. Optas LLC increased its stake in Zoetis by 36.0% in the fourth quarter. Optas LLC now owns 1,398 shares of the company's stock valued at $228,000 after purchasing an additional 370 shares during the last quarter. Finally, KPP Advisory Services LLC increased its stake in Zoetis by 6.2% during the fourth quarter. KPP Advisory Services LLC now owns 5,676 shares of the company's stock worth $925,000 after acquiring an additional 332 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock traded up $0.30 on Tuesday, reaching $172.24. 2,696,175 shares of the company were exchanged, compared to its average volume of 2,685,644. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company's 50-day moving average is $169.48 and its two-hundred day moving average is $179.39. The firm has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a P/E/G ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the prior year, the firm earned $1.36 EPS. The business's quarterly revenue was up 11.6% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This is a boost from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.16%. The ex-dividend date is Tuesday, January 21st. Zoetis's dividend payout ratio (DPR) is currently 37.59%.

Analyst Ratings Changes

Several equities research analysts have commented on ZTS shares. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target for the company. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Finally, Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Zoetis currently has an average rating of "Buy" and an average target price of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.